The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim
The impact on overall survival (OS) of first-line gefitinib (G) and erlotinib (E) and of clinical factors in advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor mutations (EGFR mut) based on meta-analysis of 1,231 patients (pts) enrolled in 6 major randomized trials.
 
Chee Lee
No Relationships to Disclose
 
Lucy Claire Davies
No Relationships to Disclose
 
Yi-Long Wu
Honoraria - AstraZeneca; Lilly; Roche Pharma AG
 
Tetsuya Mitsudomi
Honoraria - AstraZeneca; Boston Biomedical; Chugai Pharma; Daiichi Sankyo; Lilly; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Clovis Oncology; MSD; Novartis; Pfizer; Roche Pharma AG; Synta
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Akira Inoue
Honoraria - AstraZeneca; Chugai Pharma
 
Rafael Rosell
No Relationships to Disclose
 
Caicun Zhou
Consulting or Advisory Role - Boehringer Ingelheim; Lilly; Roche Pharma AG
Speakers' Bureau - Boehringer Ingelheim; Lilly; Roche Pharma AG
Research Funding - Boehringer Ingelheim (Inst); Lilly (Inst); Roche Pharma AG (Inst)
 
Kazuhiko Nakagawa
Honoraria - AstraZeneca; Chugai Pharma; Lilly
Speakers' Bureau - AstraZeneca; Chugai Pharma; Lilly
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst)
 
Sumitra Throngprasert
No Relationships to Disclose
 
Masahiro Fukuoka
Honoraria - AstraZeneca; Chugai Pharma
 
Richard J. Gralla
No Relationships to Disclose
 
Val Gebski
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - Roche Pharma AG
 
Tony Mok
Employment - The Chinese University of Hong Kong
Honoraria - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; AstraZeneca; AVEO; Biomarin; Boehringer Ingelheim; Bristol-Myers Squibb; Clovis Oncology; Eisai; Janssen; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Speakers' Bureau - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
Research Funding - AstraZeneca
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Lilly; Merck Serono; Pfizer; Roche
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly; Pfizer; Roche Pharma AG
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Clovis Oncology; Daiichi Sankyo; Lilly; Merck; MSD; Novartis; Pfizer; Roche/Genentech
Research Funding - Boehringer Ingelheim (Inst)